最新研究揭示云顶新耀耐赋康®在不同病理人群中均有显著获益 专家提示一经确诊应尽早使用

Core Insights - The recent ERA 2025 conference showcased nine new studies on the drug Nefukang® (Budesonide enteric-coated capsules), confirming its renal protective value for patients with varying baseline eGFR levels and different pathological changes [1][2][3] - Nefukang® is the first and only approved drug for the treatment of IgA nephropathy in China, the US, and Europe, without restrictions based on proteinuria levels, establishing its leadership in first-line treatment [1][4] - The studies support a "total treatment" strategy, emphasizing the importance of early intervention with Nefukang® to protect renal function and improve overall prognosis for all diagnosed patients [1][3] Study Findings - A sub-analysis of the NefIgArd study indicated that treatment with Budesonide enteric-coated capsules for nine months led to reduced proteinuria and stable renal function (eGFR) across all baseline eGFR levels during a two-year study period [2] - Another multi-center study showed significant reductions in proteinuria and stable eGFR in patients with active lesions, particularly those with endothelial cell proliferation and/or crescent formation [2][3] - The findings provide strong evidence for the application of Budesonide enteric-coated capsules in treating IgA nephropathy, offering new treatment options for clinicians [2][3] Clinical Implications - Clinicians are encouraged to initiate cause-specific treatment immediately upon diagnosis to maximize renal function protection and improve patient outcomes [3] - The CEO of Yunding Xinyao highlighted that these studies further validate Nefukang®'s benefits across different renal function levels and pathological types, supporting a new disease management strategy for IgA nephropathy [3] - The prevalence of IgA nephropathy is significantly higher in Asia, with an estimated 5 million patients in China and over 100,000 new cases annually, indicating a substantial unmet clinical need [3] Additional Research - Besides the two key studies, seven other studies presented at the conference covered efficacy prediction markers, treatment sustainability, and safety mechanisms, broadening the applicability of Nefukang® in clinical settings [4] - Nefukang® was included in the national medical insurance drug list as of November 2024, with expectations to leverage its evidence-based advantages to enhance treatment initiation upon diagnosis [4]